Floatz logo

Berzosertib

Small Cell Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
NOGITECAN
National Cancer Institute (NCI)
Phase 2BB
Vinorelbine Ditartrate
EpicentRx, Inc.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
EpicentRx, Inc.
Phase 2BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Lurbinectedin
SystImmune Inc.
Phase 3BB

View all 30 →

Same molecule, other indications

Berzosertib is also rated in:

small cell lung carcinomaActive
BBB
Indicative · Phase 2
73 / 100
View asset →
fallopian tube carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
ovarian carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →